ALK rearrangements were initially identified in large-cell lymphomas, but the discovery of the EML4-ALK fusion in NSCLC in 2007 established ALK as a key oncogenic driver in this disease [92,93]. The gene discussed is EML4; the disease is non-small cell lung carcinoma.